Determination of racemic ketorolac, ketorolac enantiomers and their metabolites in human plasma and urine by LC-UV, applied in a clinical study during and after pregnancy by Kulo, Aida et al.
1 3
DOI 10.1007/s10337-014-2670-4
Chromatographia
OrIgInal
Determination of Racemic Ketorolac, Ketorolac Enantiomers 
and Their Metabolites in Human Plasma and Urine by LC–UV, 
Applied in Clinical Study During and After Pregnancy
Aida Kulo · Nedzad Mulabegovic · Svjetlana Loga‑Zec · 
Karel Allegaert · Jan de Hoon · Rene Verbesselt 
received: 20 September 2013 / revised: 10 March 2014 / accepted: 12 March 2014 
© Springer-Verlag Berlin Heidelberg 2014
Keywords Column liquid chromatography ·  
racemic ketorolac · p-Hydroxy-ketorolac · R-Ketorolac · 
S-Ketorolac · Ketorolac glucuronide · Plasma · Urine · 
Pregnancy · Postpartum
Introduction
In non-pregnant adults, the non-steroidal anti-inflamma-
tory drug ketorolac undergoes elimination through renal 
(55–60 %) and hepatic metabolic elimination (40–45 %) 
including both phase I [oxidation via cytochrome P450 
(CYP)2C8-9 to p-hydroxy-ketorolac, 12–22 %] and phase 
II [glucuronidation via uridinediphosphateglucuronosyl-
transferase (UgT)2B7, 21–24 %] [1–3] reactions. When 
administered intravenously (IV), 91.8 % of the dose 
(1.7 mg kg−1) is retrieved in 24-h urine collection [2].
Physiological changes in pregnancy and postpartum, 
including changes in hepatic and renal functions likely 
affect ketorolac disposition [4, 5]. Despite the limited data 
on ketorolac pharmacokinetics in those women, it is fre-
quently used as analgesic in this population [6–12], as part 
of a multimodal post-caesarean analgesia [4, 13–15].
So far, high performance liquid chromatography (HPlC) 
methods were described to determine racemic ketorolac in 
human plasma [16–24], racemic ketorolac in human urine 
[16, 20, 21], p-hydroxy-ketorolac in human plasma [18], 
p-hydroxy-ketorolac in human urine [20, 21], ketorolac enan-
tiomers in human plasma [20, 22, 25–29] and ketorolac enan-
tiomers in human urine [20]. Except for solid-phase extrac-
tion for racemic ketorolac [19, 23, 24] and for ketorolac 
enantiomers [22, 29], published sample preparations include 
mainly liquid–liquid extractions for racemic ketorolac [17, 
18, 20, 21] and ketorolac enantiomers [20, 25–28, 30]. Mros-
zczak et al. [21] described ethyl acetate and hexane extraction 
Abstract In order to enhance the sensitivity and to 
develop a faster direct method for plasma and urine quan-
tification of racemic ketorolac, its metabolites (p-hydroxy-
ketorolac and ketorolac glucuronides) and ketorolac enan-
tiomers, we developed an extraction procedure based on 
solid-phase extraction combined with specific and fast 
chromatographic separation. Extraction and chromatog-
raphy resulted in cleaner chromatograms without inter-
fering compounds. In both plasma and urine, linearity of 
the standard curves for racemic ketorolac and p-hydroxy-
ketorolac was validated in the concentration range 
0.025–10 mg l−1, while for ketorolac enantiomers in the 
concentration range 0.025–5 mg l−1. The lower limit of 
quantification was two times lower than in earlier described 
methods. The developed method was suitable for direct 
quantification of racemic ketorolac, p-hydroxy-ketorolac 
and ketorolac enantiomers in plasma and urine samples in 
women at delivery and in postpartum, enabling us to docu-
ment significant intra-individual differences in pharmacoki-
netics between these physiological states.
a. Kulo (*) · J. de Hoon · r. Verbesselt 
Center for Clinical Pharmacology, KU leuven and University 
Hospitals leuven, Herestraat 49, 3000 leuven, Belgium
e-mail: aidakulo@gmail.com; aida.kulo@gmail.com
a. Kulo · n. Mulabegovic · S. loga-Zec 
Faculty of Medicine, Institute of Pharmacology,  
Clinical Pharmacology and Toxicology, University of Sarajevo, Čekaluša 90, 71000 Sarajevo, Bosnia and Herzegovina
K. allegaert 
Department of Development and regeneration,  
KU leuven and neonatology, University Hospitals leuven, 
Herestraat 49, 3000 leuven, Belgium
A. Kulo et al.
1 3
for racemic ketorolac in plasma. Wu et al. [18] used three-
stage liquid–liquid extractions with diethyl ether and hexane 
for racemic ketorolac and p-hydroxy-ketorolac in plasma. 
Similar extraction was employed by other authors for race-
mic ketorolac in plasma [17, 20]. For ketorolac enantiomers, 
indirect HPlC methods based on derivatization and using 
achiral HPlC were developed first [28–30]. However, only 
an indirect method [29] based on formation of diastereomeric 
amides gave satisfactory results while other indirect methods 
resulted in complete and rapid racemization due to alkaline 
conditions during derivatization [25]. nowadays, those assays 
are typically performed by direct HPlC methods using either 
chiral HPlC after using methyl tert-butyl ether [25], die-
thyl ether [26], pentan-2-ol [27] or ethyl acetate [20, 30] as 
extractants or a solid-phase extraction column [29]. The last 
method prevented racemization, which is mainly the result of 
usage of strong alkaline and strong acid (pH < 1) reagents. 
Except for alpha1 acid glycoprotein-based chiral column, a 
human serum stationary phase was also used [31].
For ketorolac enantiomers in human plasma, HPlC 
combined with mass spectrometry (MS) has also been 
described [32].
Because the earlier described methods are both rather 
time consuming and complicated, we aimed to develop 
a new HPlC technique to determine racemic ketorolac, 
ketorolac enantiomers and its metabolites in human 
plasma and urine. This method was subsequently applied 
to samples collected at delivery and in postpartum to quan-
tify the impact of pregnancy on ketorolac disposition.
Materials and Methods
Chemicals and reagents
racemic ketorolac and p-hydroxy-ketorolac were obtained 
from Hoffmann-la roche ltd. (Mannheim, germany), tol-
metin and naproxen from Sigma-aldrich (Schnelldorf, ger-
many). Methanol and acetonitrile were HPlC grade and 
obtained from Bisolve (Valkenswaard, The netherlands).
Citric acid, disodium hydrogen phosphate, potassium 
dihydrogen phosphate, β-glucuronidase, acetic acid, sodium 
acetate and 2-propanol were analytical grade and obtained 
from Merck (Darmstadt, germany). Millipore ultrapure water 
was obtained from a simplicity system (Millipore, Belgium), 
drug-free human urine was obtained from healthy volunteers 
and drug-free human plasma from the internal plasma bank 
(Center for Clinical Pharmacology, leuven, Belgium).
Instrumentation and Chromatographic Conditions
Solid-phase extraction columns (Bond Elut C2 100 mg, 
1 ml volume for racemic ketorolac and p-hydroxy-ketorolac, 
Bond Elut C8 100 mg, 1 ml volume for hydrolysed samples, 
Oasis HlB 30 mg, 1 ml volume for ketorolac enantiomers 
and a Vac Elut SPS24 vacuum extraction system) were used.
The HPlC system consisted of a Waters 600E HPlC-
pump (Milford, Ma, USa), a photodiode array detector 
996 (Waters) and dual UV detector 2487 (Waters) and an 
auto-injector WISP 717 plus (Waters). Waters chromato-
graphic data system Empower 2 was used for integration 
and calculation of the data.
racemic analytes were separated on a Hypersil BDS C18 
5μ column (250 × 4.6 mm i.d.) and the ketorolac enantiomers 
on a chiral agP 5μ column (100 × 4.0 mm i.d.). The mobile 
phase consisted of a mixture of acetonitrile and 15-mM potas-
sium dihydrogen phosphate buffer pH 3.0 (+0.05 % triethyl-
amine) (40/60, v/v) for racemic determination and of a mixture 
of 2-propanol and 50-mM potassium dihydrogen phosphate 
buffer pH 5.5 (5/95, v/v for plasma and 4/96, v/v for urine) 
for enantiomer separation. The mobile phases were pumped 
with a flow rate of 1 and 0.5 ml min−1, respectively. The PDa 
detector or UV detector 2487 was set at 313 nm.
Preparation of Standard Solutions and Quality Control 
Samples
Two individually weighted (1 g l−1) stock solutions of 
racemic ketorolac and p-hydroxy-ketorolac were prepared 
in methanol and stored at 4 °C for preparation of either 
the calibration standards or the quality control (QC) sam-
ples. In order to obtain calibration standards in the range 
of 0.025–10 mg l−1 for plasma or urine, appropriate meth-
anol/water (50/50, v/v) dilutions of racemic ketorolac and 
p-hydroxy-ketorolac stock solutions were performed daily 
with each new batch of samples and added to aliquots of 
drug-free human plasma or diluted blank urine. From the 
second stock solution of racemic ketorolac and p-hydroxy-
ketorolac low, middle and high QC samples at 0.1, 0.5 and 
2.5 mg l−1 were prepared in drug-free human plasma or 
diluted blank urine, then 0.65 ml was aliquoted into poly-
propylene tubes and stored at −20 °C until analysis.
Internal standard stock solutions (tolmetin for race-
mic ketorolac and p-hydroxy-ketorolac, and naproxen for 
ketorolac enantiomers) were prepared in methanol at a 
concentration of 1 g l−1, stored at 4 °C and further diluted 
to working solution of 10 and 75 g l−1, respectively.
Patient Plasma und Urine Samples
IV bolus ketorolac tromethamine (Taradyl®, roche, ander-
lecht, Belgium) was administered (30-mg ketorolac trometh-
amine, equal to 20.345 mg of ketorolac) as part of multimodal 
analgesic approach applied following caesarean delivery in 
the University Hospitals leuven, Belgium [5]. To enable 
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comparison of ketorolac PK at delivery with postpartum state, 
a group of the same eight women at delivery and 4–5 months 
postpartum were studied, using the same methodological 
approach. Five plasma samples per subject were collected at 1, 
2, 4, 6 and 8 h after the drug administration. after collection in 
lithium-heparinised tubes, blood samples were centrifuged for 
10 min at 1,350×g at 4 °C and plasma separated.
Urine samples were harvested from the first 8-h urine 
collection after drug administration.
Both plasma and urine were stored at −20 °C until anal-
ysis. Before assaying, all samples were allowed to thaw at 
room temperature for 30 min, vortexed and centrifuged for 
5 min at 4 °C at 1,350×g.
Extraction Procedures
Extraction Procedure for Free Racemic Ketorolac 
and p‑Hydroxy‑Ketorolac in Plasma and Urine
To 500 μl of drug-free human plasma or urine diluted 
in water (1/20), 50 μl of the standard ketorolac and 
p-hydroxy-ketorolac dilutions (in the range 0.025–
10 mg l−1) in methanol/water (50/50, v/v) were added. 
To all samples (drug-free human plasma or urine, patient 
plasma or urine and QCs), 50 μl of the internal standard 
tolmetin dilution (10 mg l−1) in methanol/water (50/50, v/v) 
and 500-μl citrate phosphate buffer pH 2.2 were added. In 
order to equal the volume, additional 50 μl of methanol/
water (1:1, v/v) was added to the patient samples and QCs.
after vortexing and centrifuging at 1,800×g for 5 min, 
the samples were ready for application to the solid-phase 
extraction columns (Bond Elut C2 100 mg, 1 ml volume). 
The solid-phase extraction was performed with a Vac Elut 
SPS24 vacuum extraction system. after the columns were 
activated with two times 1 ml methanol and two times 
1 ml water, applying slight vacuum to the columns, the 
prepared standards, controls and samples were passed 
through the columns at a vacuum pressure of maximum 
5 bar. Then 1-ml water was applied, followed by 1-ml 
methanol/water (10/90, v/v) and again vacuum maintained 
for 5 min. after elution of the columns was performed with 
two times 0.5 ml methanol, the eluates were evaporated to 
dryness with an airstream in a water bath at 45 °C for about 
20 min and the dried residues were dissolved in 200 μl of 
the mobile phase. Injection volumes onto the HPlC col-
umn varied between 10 and 60 μl.
Extraction Procedure for Racemic Ketorolac Glucuronides 
in Plasma and Urine
glucuronide concentrations were obtained by substraction 
of the free ketorolac or p-hydroxy-ketorolac concentrations 
from the total hydrolysed concentrations.
Hydrolysis of Samples To 200 μl of plasma or urine 
diluted in water (1/10), 250 μl 0.5 M sodium acetate buffer 
pH 5 and 50 μl of β-glucuronidase (3,000 IU) in the same 
sodium acetate buffer were added. Samples were incubated 
in a water bath at 37 °C for 4 h and then the reaction stopped 
in ice bath with 500 μl 2 M acetic acid, followed by addi-
tion of the 20 μl internal standard tolmetin (10 mg l−1).
Preparation of Standard Curves To 200 μl of plasma or 
urine diluted in water (1/10), 300 μl 0.5 M sodium acetate 
buffer pH 5, 50 μl of standard ketorolac and p-hydroxy-
ketorolac dilutions in methanol/water (50/50, v/v) (final con-
centration range 0.025–10 mg l−1), 20 μl of the internal 
standard tolmetin (10 mg l−1) in methanol–water (50/50, 
v/v) and 500 μl 2 M acetic acid were added.
after vortexing and centrifuging at 1,800×g for 5 min, 
the samples were ready for application to the solid-phase 
extraction columns (Bond Elut C8 100 mg, 1 ml volume). 
The performance of solid-phase extraction and HPlC con-
ditions were as described for the racemic ketorolac and 
p-hydroxy-ketorolac determination.
Extraction Procedure for Free Ketorolac Enantiomers 
in Plasma and Urine
To 500 μl of plasma or urine diluted in water (1/10), was 
added 50 μl of standard ketorolac dilutions in methanol/
water (50/50, v/v) (in the range 0.025–10 mg l−1), 50 μl 
of the internal standard naproxen dilution (75 mg l−1) in 
methanol–water (50/50, v/v) and as described for the race-
mic ketorolac and p-hydroxy-ketorolac determination 500-
μl citrate phosphate buffer pH 2.2. after vortexing and 
centrifuging at 1,800×g for 5 min, the samples were ready 
for application to the solid-phase extraction columns (Oasis 
HlB 30 mg, 1 ml volume). The performance of solid-phase 
extraction and HPlC conditions was as described for the 
racemic ketorolac and p-hydroxy-ketorolac determination.
Extraction Procedure for Glucuronides of Ketorolac 
Enantiomer in Urine
after several freezing–thawing cycles, the glucuronides 
of ketorolac enantiomers became instable due to possi-
ble hydrolysis, as was proved by the absence of glucuro-
nides after the described hydrolysis procedure. Only free 
ketorolac enantiomers were found.
Validation Procedures
The validation of the presented method was based on bio-
analytical method validation guidelines [33–35].
The linearity of the method was tested by analysing cal-
ibration curves with concentrations in fivefold. Calibration 
A. Kulo et al.
1 3
curves were constructed using peak–height ratios of race-
mic ketorolac, p-hydroxy-ketorolac and ketorolac enanti-
omers, over the internal standard versus the nominal ana-
lyte concentration. linear least-squares regression fit of 
the calibration curves was performed. Fitting parameters 
and back-calculated values were obtained by the software 
program Excel (Microsoft). acceptance criteria [33] for 
standard calibration samples were set as follows: 75 % 
or a minimum of six standards, when back-calculated 
[including upper limit of quantification (UlOQ)] should 
fall within ±15 %, except for the lower limit of quantifi-
cation (llOQ) when it should be ±20 % of the nominal 
value. Values falling outside these limits were discarded, 
provided they do not change the established calculation 
model. acceptance criteria for quality control samples 
were at least 67 % of QCs should be within 15 % of their 
respective nominal value, 33 % of the QCs (not all repli‑
cates at the same concentration) may be outside of 15 % of 
the nominal value.
Intra-assay precision [coefficient of variation (CV %)] 
and accuracy [percentage deviation from the nominal value 
(% dev)] were assessed by setting up standard curves using 
both five standard concentration levels and three QCs (near 
the lowest standard, near the middle and near the highest 
standard) in fivefold. Three QCs were analysed daily for 
inter-assay precision and accuracy determination.
lower limit of quantification was defined as the lowest 
concentration of the standard curve with both precision and 
accuracy within ±20 % of the nominal value.
The specificity of the method was evaluated through the 
interference with endogenous compounds from drug-free 
plasma or urine samples. The interference with other co-
medicated drugs was checked by analysing patient samples.
The absolute analytical recovery of racemic ketorolac, 
p-hydroxy-ketorolac, tolmetin, R-ketorolac, S-ketorolac 
and naproxen can be determined by comparing the ana-
lytical results for extracted samples with those for stand-
ard solutions. The overall recovery was calculated over the 
entire range of calibration standards.
The stability was assessed by assaying the QCs in three 
freeze–thaw cycles and also by leaving it at room tempera-
ture for 24 h (short-term temperature stability). Freeze–
thaw cycles were performed as follows: four aliquots of the 
low and high ketorolac and p-hydroxy-ketorolac concentra-
tions (0.1 and 2.5 mg l−1) and R-ketorolac and S-ketorolac 
concentrations (0.05 and 1.25 mg l−1) were stored at 
−20 °C for 24 h and thawed unassisted at room tempera-
ture; when completely thawed, samples were refrozen for 
24 h under the same conditions. The freeze–thaw cycle 
was repeated two more times and the samples were ana-
lysed on the third cycle. Short-term temperature stability 
was assessed as four aliquots of the low and high ketorolac, 
p-hydroxy-ketorolac, R-ketorolac and S-ketorolac 
concentrations were thawed at room temperature and kept 
at this temperature for 24 h before being further analysed. 
The long-term stability of ketorolac, p-hydroxy-ketorolac, 
tolmetin and naproxen stock solutions was evaluated at 
4 °C for more than 1 month.
Results and Discussion
We developed a direct HPlC method for determination of 
racemic ketorolac, the glucuronides and ketorolac enan-
tiomers. Compared to earlier described HPlC methods 
[19, 29], we used different solid-phase extraction col-
umns and other chromatographic conditions. Three dif-
ferent solid-phase columns were used: Bond Elut C2 for 
racemic ketorolac, Bond Elut C8 for hydrolysed ketorolac 
and p-hydroxy-ketorolac and Oasis HlB for ketorolac 
enantiomers, improving selectivity and specificity of our 
method.
The new methods compare well with previously pub-
lished methods with regard to suitability and precision, but 
are more sensitive, faster and easier to perform.
additional advantages of the present methods are the 
identical procedures for racemic ketorolac and ketorolac 
enantiomers determination in both plasma and urine.
a very simple method for racemic ketorolac extraction 
from plasma was described recently, but the method for 
urine sample preparation was significantly different from 
those described in plasma [16]. In contrast, we described 
simpler, identical extraction procedures for plasma and 
urine, shortening the time for ketorolac and p-hydroxy-
ketorolac urine extraction significantly.
Hydrolysis of samples was earlier described only briefly 
by Kauffman et al. [20] with no validation data.
representative chromatograms of racemic ketorolac 
(KTr), p-hydroxy-ketorolac (HO-KTr) and tolmetin 
(TMT) in patient’s plasma and urine samples are shown in 
Fig. 1, and for R-ketorolac (r-KTr), S-ketorolac (S-KTr) 
and naproxen (naP) in patient’s plasma and urine sam-
ples in Fig. 2. For ketorolac enantiomers, chromatography 
sequence is based on similar chromatographic conditions 
as described in the literature. no enantiomers of HO-KTr 
were ever separated, and there is no information on this 
topic in the literature.
Calibration Curve and linearity
as the variance increased in proportion to the concentra-
tion, the best fit was obtained using a weighing factor of 
1/concentration2. Calibration curves were prepared for 
ketorolac and p-hydroxy-ketorolac in the range from 0.025 
to 10 mg l−1, and for R-ketorolac and S-ketorolac in the 
range from 0.025 to 5 mg l−1 for both plasma and urine 
Determination of Racemic Ketorolac, Ketorolac Enantiomers and Their Metabolites
1 3
samples. linearity of calibration curves for plasma and for 
urine was found with calculated regressions as showed in 
Table 1. Wider linearity range for racemic ketorolac was 
observed in our method compared to earlier published 
methods [16–18, 21]. a wider range of the calibration 
curve for ketorolac enantiomers (linearity up to 20 mg l−1) 
was observed earlier [25, 26], but this is of minor clinical 
relevance in the measurement of low ketorolac enantiomers 
concentrations (up to 2.01 mg l−1) observed in our clinical 
plasma samples.
Precision and accuracy
as a result of the described improvements, we obtained 
satisfactory intra-assay precision and accuracy as cali-
bration standards and QCs deviated from the nominal 
value in the acceptable range of CV % and % devia-
tion (all below 15 %, except for p-hydroxy-ketorolac 
and R-ketorolac in urine, and for S-ketorolac in plasma). 
Inter-assay precision and accuracy of three QCs for 
each ketorolac, p-hydroxy-ketorolac, R-ketorolac and 
S-ketorolac in plasma and urine are presented in Table 2. 
Comparable satisfactory precision was shown in earlier 
studies for racemic ketorolac, e.g. CV <9 % [17, 20], 
<5.3 % in plasma and <7.2 % in urine [16]. For ketorolac 
enantiomers, comparable precision was found by direct 
method [28] and higher CV  % than found by other 
authors e.g. (<10 % [20] and 3–8 %) [22, 30].
limits of Quantification
The llOQ for ketorolac, p-hydroxy-ketorolac, R-ketorolac 
and S-ketorolac obtained in our study was 0.025 mg l−1, 
being the lowest concentration of the standard curve with 
acceptable precision and accuracy (with a coefficient 
of variation lower than 20 %). The llOQ for racemic 
ketorolac in plasma was two times lower when compared 
to some earlier studies [16, 18, 19], but also higher com-
pared to others in plasma, e.g. 0.005 [20, 36] or 0.003 [17] 
as well as in urine [16]. This low llOQ is appropriate for 
use in pharmacokinetic studies.
The llOQ for ketorolac enantiomers was comparable to 
some earlier studies, e.g. 0.02 [22, 29, 30], but also higher 
compared to others, e.g. 0.01 [37] or 0.005 [20, 25, 26].
The UlOQ for plasma and urine was set as 10 mg l−1 
for ketorolac and p-hydroxy-ketorolac, and as 5 mg l−1 for 
R-ketorolac and S-ketorolac. Urine samples with concen-
trations higher than this were re-analysed after appropriate 
dilution.
Selectivity and Specificity
no interferences with endogenous compounds from pooled 
human drug-free plasma and drug-free urine were detected 
using the extraction and chromatographic conditions as 
described for ketorolac, p-hydroxy-ketorolac, R-ketorolac 
and S-ketorolac, tolmetin and naproxen.
Fig. 1  Chromatogram of a blank and patient plasma after drug 
administration [ketorolac (KTr) plasma concentration 1.73 mg l−1] 
and internal standard tolmetin (TMT), b blank and patient urine 
sample [KTr urine concentration 5.34 mg l−1, p-hydroxy-ketorolac 
(HO-KTr) urine concentration 1.92 mg l−1] and TMT, extracted as 
described in “Methodology”
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Extraction Method and recovery
analytical recovery (%) of ketorolac, p-hydroxy-
ketorolac, R-ketorolac, S-ketorolac, and internal stand-
ards tolmetin were almost around 100 %. The relative 
analytical recovery was determined by comparing peak 
heights of spiked QCs with peak heights of calibration 
standards.
Compared to our study where average recovery of race-
mic ketorolac in plasma was 118.1 % and in urine 126.9 %, 
in recently published studies it was 99.3 % [16], 98.4 % 
[18], 80–90 % [17] in plasma and 80.3 % [16] in urine.
Fig. 2  Chromatogram of a blank and patient plasma sample 
after drug administration [R-ketorolac (r-KTr) plasma concen-
tration 1.15 mg l−1, S-ketorolac (S-KTr) plasma concentration 
0.37 mg l−1] and internal standard naproxen (naP), b blank and 
patient urine sample collected 8 h after drug administration (r-KTr 
urine concentration 0.075 mg l−1, S-KTr urine concentration 
0.095 mg l−1), and naP, extracted as described in “Methodology”
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average recovery of R-ketorolac and S-ketorolac in 
plasma using our method (101 and 96.6 %) was compara-
ble to earlier found recoveries 88.4–110 % and 90.1–110 % 
found [29], and better compared to other published ones, 
e.g. 74.33 and 73.15 % [25], 91–94 % and 91–96 % [30].
Stability
Quality control samples were tested at different tempera-
ture conditions and stability of ketorolac was satisfactory, 
with results deviating less than 10 % from nominal values. 
For p-hydroxy-ketorolac, however, deviation higher than 
20 % was found. When stored at 4 °C, stock solutions of 
ketorolac and p-hydroxy-ketorolac and ketorolac enanti-
omers remained stable for more than 3 months, as proven 
by the reproducibility of the slope of the daily calibration 
curves (Table 3). Plasma and urine samples were stable 
for several months when stored at −20 °C, less than 15 % 
deviation was found re-analysing samples after more than 
4 months.
Table 1  linearity of calibration curves: free ketorolac (KTr), p-hydroxy-ketorolac (HO-KTr), free S-ketorolac (S-KTr) and R-ketorolac 
(r-KTr) enantiomers
linearity of calibration curves
linear equation (y = a + bx) R (correlation coefficient) linear equation (y = a + bx) r (correlation coefficient)
KTr HO-KTr
Plasma free −001 + 1.91x 0.9992 −0.00 + 3.11x 0.9966
Urine free 0.00 + 1.87x 0.9997 0.16 + 3.52x 0.9981
Plasma hydrolysed 0.01 + 1.71x 0.9988 0.38 + 2.79x 0.9987
Urine hydrolysed 0.01 + 1.69x 0.9998 −0.01 + 2.92x 0.9991
r-KTr S-KTr
Plasma free 0.00 + 3.58x 0.9974 −0.03 + 2.94x 0.9965
Urine free −0.00 + 4.57x 0.9974 0.01 + 3.28x 0.9964
Table 2  Inter-assay precision and accuracy [expressed as a mean for 
all plasma and urine samples analysed on free ketorolac (KTr) and 
p-hydroxy-ketorolac (HO-KTr), and plasma and urine samples ana-
lysed on free S-ketorolac (S-KTr) and R-ketorolac (r-KTr) enanti-
omers] of quality control samples extracted from plasma and urine
nominal  
concentration  
(mg l−1)
Inter-assay precision and accuracy
Obtained concentration (mg l−1) Precision (CV %) accuracy (% dev)
Plasma (34 days) Urine (10 days) Plasma (34 days) Urine (10 days) Plasma (34 days) Urine (10 days)
KTr
 0.1 0.09 0.09 10.5 6.2 −8.8 −7.5
 0.5 0.47 0.46 8.1 4.6 −6.7 −7.9
 2.5 2.41 2.32 8.8 5.3 −3.8 −7.2
HO-KTr
 0.1 0.09 0.10 12.9 15.1 −8.1 1.7
 0.5 0.47 0.50 10.9 4.4 −5.0 0.0
 2.5 2.49 2.56 10.8 8.4 −0.4 2.2
Plasma (21 days) Urine (4 days) Plasma (21 days) Urine (4 days) Plasma (21 days) Urine (4 days)
r-KTr
 0.05 0.05 0.05 13.5 15.2 −8.2 0.2
 0.25 0.23 0.22 9.9 5.4 −8.5 −12.6
 1.25 1.18 1.15 9.1 5.5 −5.6 −8.3
S-KTr
 0.05 0.05 0.05 15.2 14.9 −3.3 8.0
 0.25 0.23 0.22 10.3 12.1 −6.6 −14.0
 1.25 1.18 0.15 9.3 5.9 −5.8 −8.0
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application of the Methodology in Plasma and Urine 
Samples of Women at Delivery and in Postpartum
as we proved selectivity, linearity, precision and accuracy, 
this assay was successfully applied in ketorolac pharma-
cokinetics studies in the same cohort of women at delivery 
and 4–5 months postpartum (paired study design) [15].
To illustrate the applicability of the method, plasma 
and urine concentrations of racemic ketorolac, p-hydroxy-
ketorolac, R-ketorolac and S-ketorolac were quantified in 
80 plasma samples and in 16 urine samples collected in 
eight women at delivery and in 4–5 months postpartum. 
racemic ketorolac glucuronide in urine was also quanti-
fied by hydrolysis of samples. Data on racemic ketorolac 
in young women including women at delivery and in post-
partum with significant differences in disposition in the 
same group of women at delivery and 4–5 months postpar-
tum have recently been reported by our group [4, 13–15]. 
Data on enantiomer-specific disposition are of relevance 
and in the present study, we would like to focus on phar-
macokinetics’ differences between ketorolac enantiomers 
in hereby mentioned group of young women. representa-
tive chromatograms of patient plasma and urine sample are 
shown in Figs. 1 and 2.
Concentrations in plasma ranged from 0.06 to 
2.01 mg l−1 and 0.01 to 1.13 mg l−1 for R-ketorolac 
and S-ketorolac, respectively, and in urine from 1.16 to 
23.14 mg l−1 and 1.02 to 21.95 mg l−1, respectively.
a preliminary interpretation of time–concentration 
profiles of racemic ketorolac and ketorolac enantiom-
ers in the same group of women at delivery and in post-
partum following single IV administration of ketorolac 
(30 mg) is shown in Fig. 3. Median clearance and distribu-
tion volume estimates for racemic ketorolac were 0.05 vs. 
0.04 l h−1 kg−1 and 0.19 vs. 0.16 l kg−1, for R-ketorolac 
0.07 vs. 0.05 l h−1 kg−1 and 0.29 vs. 0.22 l kg−1, and 
for S-ketorolac 0.22 vs. 0.13 l h−1 kg−1 and 0.59 vs. 
0.42 l kg−1. Pharmacokinetic parameters were calcu-
lated as reported earlier (racemic ketorolac) [4]. This con-
firms both racemic ketorolac and the enantiomer-specific 
elimination to be faster in women at delivery compared 
to the same women 4–5 months postpartum. as proven 
in non-pregnant adults [22, 38] and children [20, 22, 39], 
S-ketorolac is cleared faster compared to R-ketorolac.
In addition, by analysing both plasma and urine sam-
ples, we could quantify the portion of racemic ketorolac, 
p-hydroxy-ketorolac, R-ketorolac, S-ketorolac and 
ketorolac glucuronide excreted in urine and the percent-
age of dose recovered in 8-h urine collections (Table 4). 
We documented higher contribution of oxidative meta-
bolic pathways to overall ketorolac clearance at delivery 
Table 3  long-term stability 
of slopes of standard curves/
stock solutions: free ketorolac 
(KTr), p-hydroxy-ketorolac 
(HO-KTr), free S-ketorolac 
(S-KTr) and R-ketorolac 
(r-KTr) enantiomers
Mean slope Precision (CV %) accuracy (% dev)
KTr HO-KTr KTr HO-KTr KTr HO-KTr
Plasma free (n = 25) 1.582 1.476 6.211 16.711 0.098 0.246
Plasma hydrolysed (n = 13) 1.707 2.948 14.291 15.083 0.245 0.445
Urine free (n = 6) 1.598 2.443 5.013 8.455 0.081 0.207
Urine hydrolysed (n = 4) 1.728 3.048 2.422 3.703 0.041 0.115
r-KTr S-KTr r-KTr S-KTr r-KTr S-KTr
Plasma free (n = 21) 3.782 3.012 12.177 11.299 0.462 0.341
Urine free (n = 3) 4.290 3.147 2.597 3.000 0.095 0.114
Fig. 3  Mean ± SD time–concentration profiles with a trend line 
assuming a non-compartmental model of a racemic ketorolac and 
b R-ketorolac and S-ketorolac, in eight women at delivery and 
4–5 months postpartum
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compared to 4–5 months postpartum (average 38 vs. 28) 
[13]. The combined analysis of plasma and urine samples 
should enable us to search for covariates of the ketorolac 
clearance capacity in young women including women at 
delivery and in postpartum as vulnerable populations.
To the best of our knowledge, the most important advan-
tages of our methodology compared to already available 
methods are the same quantification procedures for plasma 
and urine, simultaneous analysis of racemic ketorolac and 
p-hydroxy-ketorolac and specific ketorolac enantiomers 
determination.
Conclusion
an accurate, specific, sensitive and rapid HPlC method 
for quantification in both human plasma and urine was 
developed and validated for the determination of ketorolac, 
p-hydroxy-ketorolac, R-ketorolac and S-ketorolac. The 
method was subsequently applied in clinical plasma and 
urine samples, indicating its reliability and suitability for 
subsequent use in pharmacokinetic studies. Based on plasma 
and urine analysis we suggest that, when compared to non-
pregnant women, overall ketorolac clearance is increased 
in women at delivery, due to increased R-ketorolac as well 
as S-ketorolac clearances. Similar to other populations, 
S-ketorolac is cleared faster compared to R-ketorolac.
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